InMed Pharmaceuticals Exits BayMedica to Refocus on Pipeline

InMed Pharmaceuticals ( (INM) ) has provided an update.

InMed Pharmaceuticals said that on March 4, 2026, its board ratified BayMedica LLC’s decision to wind down and exit its commercial operations in rare, non-intoxicating cannabinoids before the end of the fiscal year ending June 30, 2026, in response to the expected impact of H.R. 5371, which would prohibit aspects of BayMedica’s business from November 12, 2026. During the wind-down period, BayMedica will continue limited sales and manufacturing, while InMed will incur about $550,000 in severance and $120,000 in other wind-down costs, then shift to focus exclusively on advancing its pharmaceutical pipeline, including drug candidates INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration.

The company expects these wind-down expenditures to be partially offset by profits from product sales before operations cease, although it cautioned that actual costs, timing and additional charges could differ materially from current estimates. On March 6, 2026, InMed issued a press release detailing the decision and provided unaudited pro forma financial information to reflect BayMedica’s commercial operations as discontinued, underscoring a strategic pivot away from commercial cannabinoid ingredients toward clinical-stage drug development.

The most recent analyst rating on (INM) stock is a Hold with a $0.73 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.

Spark’s Take on INM Stock

According to Spark, TipRanks’ AI Analyst, INM is a Neutral.

The score is held down mainly by weak financial performance (large continuing losses and cash burn with added uncertainty from inconsistent TTM vs annual figures) and bearish technicals (price below key moving averages and negative MACD). Valuation provides limited support due to negative earnings, while recent corporate updates show promising R&D progress but are offset by liquidity and regulatory risks.

To see Spark’s full report on INM stock, click here.

More about InMed Pharmaceuticals

InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing cannabinoid-based pharmaceutical drug candidates. Through its now-winding-down BayMedica LLC subsidiary, it has also operated in the commercial market for rare, non-intoxicating cannabinoids, which has been the company’s only revenue-generating business segment.

Average Trading Volume: 101,792

Technical Sentiment Signal: Sell

Current Market Cap: $2.57M

For an in-depth examination of INM stock, go to TipRanks’ Overview page.